We treated 7402-EV and 7402-MUC1 cells with exogenous TGF-β1 and the TβR inhibitor and found that they had no effect on HCC cell proliferation, JNK activation and the switch in Smad3 signaling. This evidence concerns the gene SMAD3 and hepatocellular carcinoma.